ICM-012 / iCoat Medical - LARVOL DELTA

A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys (clinicaltrials.gov) - P2/3 | N=200 | Not yet recruiting | Sponsor: iCoat Medical AB | Trial completion date: Jul 2026 ➔ Dec 2026 | Initiation date: Jan 2025 ➔ Sep 2025 | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Reperfusion Injury • Transplantation

First-in-Human Phase 2a (ATMIRe) Trial of Ex Vivo Allograft Treatment with iCM012 to Mitigate Ischemia-Reperfusion Injury in Kidney Transplantation (KIDNEY WEEK 2024) - P1/2 | "iCM012 demonstrated a favorable safety profile and showed promising efficacy in mitigating IRI and preserving allograft function within a 12-month follow-up. These findings strongly support further investigation in larger, multicenter trials to confirm its therapeutic potential in kidney transplantation."

P1 data • P2a data • Preclinical • Cardiovascular • Inflammation • Reperfusion Injury • Transplantation • CST3 • FABP1 • IL18 • KIM1

FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation (clinicaltrials.gov) - P1/2 | N=18 | Completed | Sponsor: iCoat Medical AB | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Reperfusion Injury • Transplantation

FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation (clinicaltrials.gov) - P1/2 | N=18 | Active, not recruiting | Sponsor: iCoat Medical AB | Phase classification: P1 ➔ P1/2

Phase classification • Cardiovascular • Reperfusion Injury • Transplantation

FIH (First in Human) Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: iCoat Medical AB | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2023 ➔ May 2024 | Trial primary completion date: Apr 2023 ➔ Jul 2023

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Reperfusion Injury • Transplantation